Teerlink, J.R. Diaz, R. Michael Felker, G. McMurray, J.J.V. Metra, M. Solomon, S.D. Adams, K.F. Anand, I. Arias-Mendoza, A. Biering-Sorensen, T. Bohm, M. Bonderman, D. Cleland, J.G.F. Corbalan, R. Crespo-Leiro, M.G. Dahlstrom, U. Echeverria, L.E. Fang, J.C. Filippatos, G. Fonseca, C. Goncalvesova, E. Goudev, A.R. Howlett, J.G. Lanfear, D.E. Li, J. Lund, M. Macdonald, P. Mareev, V. Momomura, S. O'Meara, E. Parkhomenko, A. Ponikowski, P. Ramires, F.J.A. Serpytis, P. Sliwa, K. Spinar, J. Suter, T.M. Tomcsanyi, J. Vandekerckhove, H. Vinereanu, D. Voors, A.A. Yilmaz, M.B. Zannad, F. Sharpsten, L. Legg, J.C. Varin, C. Honarpour, N. Abbasi, S.A. Malik, F.I. Kurtz, C.E., Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure, The New England journal of medicine, (384), 105-116, 2021, Massachussetts Medical Society,